Last reviewed · How we verify

standard statin therapy

Beijing Anzhen Hospital · FDA-approved active Small molecule ✓ Verified May 2026 Quality 5/100

standard statin therapy is a Small molecule drug developed by Beijing Anzhen Hospital. It is currently FDA-approved.

Standard statin therapy is a small molecule intervention used to treat various conditions, including chronic nephropathy, proteinuria, hypertension, foot ulcers, and arteriosclerosis obliterans. Statins, such as fluvastatin, are added to existing treatments like ACE-inhibitors and angiotensin receptor antagonists to manage these conditions.

At a glance

Generic namestandard statin therapy
SponsorBeijing Anzhen Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about standard statin therapy

What is standard statin therapy?

standard statin therapy is a Small molecule drug developed by Beijing Anzhen Hospital.

Who makes standard statin therapy?

standard statin therapy is developed and marketed by Beijing Anzhen Hospital (see full Beijing Anzhen Hospital pipeline at /company/beijing-anzhen-hospital).

What development phase is standard statin therapy in?

standard statin therapy is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing